arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

10x Genomics, Inc.

TXG
$57.97 ▼ -9.52 (-14.11%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
10 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

10x Genomics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.2B
Dividend Yield —
Revenue Growth 5.2% ↗
Op. Margin -9.5% ↗
ROIC -8.4% ↗
FCF / Share $1.04 ↗
Trailing P/E —
Price / Book 9.3x
FCF Yield 1.8%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

10-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$642.82M
↑ +5.2% —
Net Income Profit after all expenses
$-43.54M
↑ +76.2% —
Operating Margin Operating profit as % of sales
-9.5%
↑ +70.2% 16th
FCF / Share Free cash flow per share
$1.04
↑ +2292.9% —
Long-Term Debt Long-term obligations
$29.72M
↑ +16.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
39
Returns ↑
38
Cash Quality
5

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 36 quarters